These therapies target either the enhanced proliferative capacity of ovarian cancer cells caused by mutations in ARID1A and SMARCA4 or directly promote apoptosis of the tumour cells to achieve therapeutic goals. This evidence concerns the gene ARID1A and ovarian carcinoma.